Session Information
Session Type: Abstract Submissions (ACR)
Background/Purpose
Systemic inflammation has been linked to increased frequency of metabolic syndrome (MetS) in autoimmune diseases. However, there are no studies concerning the frequency of this complication and adipocytokine sera profile in Primary Sjögren’s syndrome (SS).
The aim of this study was to evaluate the frequency of MetS and serum levels of inflammatory cytokines, B-cell activating factor (BAFF) and adipocytokines in SS patients
Methods
Seventy-one female SS patients (American-European Consensus Group Criteria), aged 18-65 years and 71 healthy women matched for age and race were enrolled in this case-control study. Clinical data were collected by a standardized questionnaire and physical examination at inclusion. Serum levels of glucose, total cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides, interleukin-1 beta (IL-1b), IL-6, BAFF, insulin, leptin, adiponectin, visfatin, resistin, ghrelin and plasminogen activator inhibitor-1 (PAI-1) were determined for all patients and controls. MetS (International Diabetes Federation) and disease activity [(EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI)] were also determined.
Results Patients and controls were comparable regarding mean age (47.6 ± 10.3 vs. 47.2 ± 10.3 years, p=0.833), ethnicity (white: 77.5 vs. 77.5 %, p=1.000), body mass index (BMI) (27.6 ± 6.4 vs. 26.7 ± 3.6 kg/m2, p=0.783), smoking (p=0.538), sedentary lifestyle (p=0.847) and menopause (p=0.502). In contrast, MetS (39.4 vs. 16.9%, p=0.005), hypertension (32.4 vs. 11.3%, p=0.004) and dyslipidemia (22.5 vs. 4.2%, p=0.002) were more frequent in patients than controls in spite of similar abdominal and hip circumferences (p>0.05). No differences were observed regarding glucose (p=0.062), insulin (p=0.271) and HOMA-IR (p=0.662). Serum levels of IL-1b (p=0.008), IL-6 (p<0.0001), BAFF (p<0.0001), resistin (p<0.0001) and adiponectin (p=0.001) were higher in patients than in controls. Further analysis showed that SS patients with (n=28) and without (n=43) MetS were similar regarding age (p=0.111) and race (p=0,773). In contrast, the first group had higher BMI, abdominal circumference, cholesterol/LDL/VLDL, triglycerides, insulin and leptin levels, HOMA-IR score, and higher frequencies of hypertension and diabetes (p<0.05). ESSDAI (p=0.240), prednisone use (35.7 vs. 23.3%, p=0.289), current (3.0 ± 4.5 vs. 1.6 ± 3.2 mg/day, p=0.299) and cumulative dose (p=0.495) were similar in both groups. Otherwise, IL-1b levels were higher in SS patients with MetS than those without MetS (83.1 ± 187.6 vs. 8.4 ± 27.7 pg/mL, p=0.046). Multivariate analysis with adjustment for age, ethnicity, current and cumulative prednisone doses and usage time revealed that MetS group had higher values of hypertension (p=0.010), HOMA-IR (p=0.001), LDL (p=0.041), VLDL (p=0.001), triglycerides (p=0.001), glucose (p=0.045), insulin (p=0.006), leptin (p=0.008) and IL-1b (p=0.048).
Conclusion
This study identified a high frequency of MetS and an abnormal adipocytokine profile in SS patients. The interesting association of MetS with elevated IL-1b suggests that inflammation plays an important role in its pathogenesis in SS.
Disclosure:
K. L. Augusto,
None;
E. Bonfá,
None;
R. M. R. Pereira,
None;
C. Bueno,
None;
V. S. T. Viana,
None;
S. G. Pasoto,
None.
« Back to 2014 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/metabolic-syndrome-adipocytokines-and-inflammation-in-sjogrens-syndrome/